Therapeutic agent for spinal cord injury
AssigneeLife Science Institute, Inc.
InventorsMakoto KAWAMURA, Naoya MASUTOMI
Life of this patent
Estimating the term…
Abstract
A cell product for treatment of spinal cord injury, comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. Preferably, the spinal cord injury is complete or incomplete spinal cord injury.
Claims6
A method of treating a spinal cord injury, comprising administering a composition comprising SSEA-3 (Stage-Specific Embryonic Antigen-3)-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell.
A method of treating a spinal cord injury comprising administering a therapeutic amount of a composition comprising isolated Muse cells wherein said isolated Muse cells have
- all of the characteristics:
- (i) having low or no telomerase activity;
- (ii) capable of differentiating into any of tridermic cells;
- (iii) showing no neoplastic proliferation;
- (iv) having self-renewal capacities;
- (v) SSEA-3-positive;
- (vi) CD105-positive;
- and
- (vii) do not express either CD 117 or CD 146.
Dependencies are inferred from the claim text.